Tags : POC Data

Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1

Shots: The P-II BLAZE-1 study involves assessing of LY-CoV555 and LY-CoV01 for symptomatic COVID-19 in the outpatient setting. The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups i.e. LY-CoV555 (700mg/2800mg/7000 mg) vs PBO The 1EPs i.e. change from baseline in viral load @11days was met with 2800mg dose level, but not the others. […]Read More